Clinical Trials for Hepatitis Delta Virus in the WHO African region: A neglected virus among neglected viruses.

IF 14.3 1区医学 Q1 INFECTIOUS DISEASES

Journal of Infection Pub Date : 2025-05-21 DOI:10.1016/j.jinf.2025.106514

Marion Delphin, James Campbell, Eloi R Verrier, Motswedi Anderson, Gloria Sukali, Tongai Maponga, Alexander Stockdale, Philippa C Matthews

{"title":"Clinical Trials for Hepatitis Delta Virus in the WHO African region: A neglected virus among neglected viruses.","authors":"Marion Delphin, James Campbell, Eloi R Verrier, Motswedi Anderson, Gloria Sukali, Tongai Maponga, Alexander Stockdale, Philippa C Matthews","doi":"10.1016/j.jinf.2025.106514","DOIUrl":null,"url":null,"abstract":"Objectives: We set out to evaluate the extent to which Hepatitis Delta Virus (HDV) Clinical Trials (CT) include populations from the World Health Organisation (WHO) African region, aiming to highlight inequities and advocate for global investment in inclusive HDV research.Methods: We screened the clinicaltrial.gov and the WHO International Clinical Trials Registry Platform (ICTRP) repositories for 'Hepatitis Delta virus' and 'HDV' related CT. Datasets were merged using R v.4.2.1. We classified studies according to location and associated WHO region.Results: We identified a total of 47 CT on HDV, mainly conducted in Europe (69.3%), Western Pacific (19.6%) and the Americas (8.5%). Despite the highest estimated anti-HDV seroprevalence in the general population, there were no CT registered in the WHO African region. CT are still predominantly done in the regions of initial drug discovery, as seen with bulevirtide (Europe) and lonafarnib (Americas).Conclusion: HDV-focused CT are needed in the WHO African region, as the region with the highest disease burden, and unique genotypes (5-8); to evaluate efficacy of novel anti-HDV compounds and to ensure that new treatments can be distributed and deployed as they become available.","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":" ","pages":"106514"},"PeriodicalIF":14.3000,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Infection","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jinf.2025.106514","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: We set out to evaluate the extent to which Hepatitis Delta Virus (HDV) Clinical Trials (CT) include populations from the World Health Organisation (WHO) African region, aiming to highlight inequities and advocate for global investment in inclusive HDV research.

Methods: We screened the clinicaltrial.gov and the WHO International Clinical Trials Registry Platform (ICTRP) repositories for 'Hepatitis Delta virus' and 'HDV' related CT. Datasets were merged using R v.4.2.1. We classified studies according to location and associated WHO region.

Results: We identified a total of 47 CT on HDV, mainly conducted in Europe (69.3%), Western Pacific (19.6%) and the Americas (8.5%). Despite the highest estimated anti-HDV seroprevalence in the general population, there were no CT registered in the WHO African region. CT are still predominantly done in the regions of initial drug discovery, as seen with bulevirtide (Europe) and lonafarnib (Americas).

Conclusion: HDV-focused CT are needed in the WHO African region, as the region with the highest disease burden, and unique genotypes (5-8); to evaluate efficacy of novel anti-HDV compounds and to ensure that new treatments can be distributed and deployed as they become available.

查看原文本刊更多论文

世卫组织非洲区域丁型肝炎病毒临床试验：被忽视病毒中的被忽视病毒。

目的：我们开始评估丁型肝炎病毒（HDV）临床试验（CT）在多大程度上包括世界卫生组织（WHO）非洲地区的人群，旨在强调不平等并倡导全球投资于包容性的丁型肝炎病毒研究。方法：我们筛选了clinicaltrial.gov和WHO国际临床试验注册平台（ICTRP）库中“丁型肝炎病毒”和“HDV”相关的CT。使用R v.4.2.1合并数据集。我们根据地点和相关的世卫组织区域对研究进行分类。结果：我们共发现47例HDV CT，主要在欧洲（69.3%）、西太平洋（19.6%）和美洲（8.5%）进行。尽管在一般人群中估计的抗hdv血清患病率最高，但世卫组织非洲区域没有登记的CT。CT仍然主要在最初发现药物的地区进行，如布利韦肽（欧洲）和洛那法尼（美洲）。结论：世卫组织非洲区域需要以艾滋病毒为重点的CT，因为该区域疾病负担最重，而且基因型独特（5-8）；评估新型抗艾滋病毒化合物的疗效，并确保一旦有新的治疗方法可用，就可以分发和部署。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Infection 医学-传染病学

CiteScore

45.90

自引率

3.20%

发文量

475

审稿时长

16 days

期刊介绍： The Journal of Infection publishes original papers on all aspects of infection - clinical, microbiological and epidemiological. The Journal seeks to bring together knowledge from all specialties involved in infection research and clinical practice, and present the best work in the ever-changing field of infection. Each issue brings you Editorials that describe current or controversial topics of interest, high quality Reviews to keep you in touch with the latest developments in specific fields of interest, an Epidemiology section reporting studies in the hospital and the general community, and a lively correspondence section.